If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Express Scripts to add Zepbound to National Preferred Formulary
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Subscribe To Our Newsletter & Stay Updated
